Background: The current treatment of Chagas disease, endemic in Latin America and emerging in several countries, is limited by the frequent side effects and variable efficacy of benznidazole. Natural products are an important source for the search for new drugs. Aim/hypothesis: Considering the great potential of natural products as antiparasitic agents, we investigated the anti-Trypanosoma cruzi activity of a concentrated ethanolic extract of Physalis angulata (EEPA). Methods: Cytotoxicity to mammalian cells was determined using mouse peritoneal macrophages. The antiparasitic activity was evaluated against axenic epimastigote and bloodstream trypomastigote forms of T. cruzi, and against amastigote forms using T. cruzi-infected macrophages. Cell death mechanism was determined in trypomastigotes by flow cytometry analysis after annexin V and propidium iodide staining. The efficacy of EEPA was examined in vivo in an acute model of infection by monitoring blood parasitaemia and survival rate 30 days after treatment. The effect against trypomastigotes of EEPA and benznidazole acting in combination was evaluated.
Introduction
Chagas disease, a zoonosis caused by the hemoflagellate protozoan Trypanosoma cruzi, remains a serious health problem in many Latin American countries, where it is an endemic disease that affects approximately 10 million people (Rassi et al. 2010) . It is estimated that over 400.000 individuals are infected in non-endemic areas, mainly in the USA and in European countries (Coura and Viñas 2010) . Once the individual has been infected by T. cruzi, there is no effective treatment and the development of a vaccine is still in experimental stage (Gupta et al. 2013; Maya et al. 2007) . The current treatment is based on the 2-nitroimidazole benznidazole (LAFEPE, Brazil), which http://dx.doi.org/10.1016/j.phymed.2015.07.004 0944-7113/© 2015 Elsevier GmbH. All rights reserved.
is recommended for all acute, early chronic and reactivated cases (Da Silva et al. 2011) . Its inefficacy against the chronic phase of the disease, allied to many side effects which frequently lead to treatment interruption (Bahia et al. 2012; Urbina 2009 ) encourages the search for alternative compounds for a better treatment for Chagas disease.
In the continuous search for new drugs, natural products are an important source of compounds to a large number of illnesses (Newman and Cragg 2012) . A considerable number of plant-derived compounds are nowadays recognized for their antiparasitic properties (Negi et al. 2014; Rocha et al. 2005; Singh et al. 2014; Wink 2012 ). An example of plant species with active compounds is the Solanaceae Physalis angulata L., an annual herb widespread in many tropical countries and widely used in folk medicine (Soares et al. 2003; Tomassini et al. 2000) . Previously, our research group demonstrated the antiparasitic properties of seco-steroids physalins isolated from P. angulata against Plasmodium falciparum and different Leishmania species (Guimarães et al. 2009 (Guimarães et al. ,2010 Sá et al. 2011 ). More recently, it was also reported that physalins, specifically B and F, are endowed with a strong anti-T. cruzi activity against different evolutive forms of T. cruzi (Meira et al. 2013 ). Isolating physalins is quite costly, time consuming and affords low yields, aspects which hamper the use of isolated physalins for a neglected disease. To overcome this, a feasible alternative is the use of a Physalis angulata extract. In fact, the concentrated ethanolic extract from P. angulata (EEPA) is nonmutagenic, presents low toxicity in mice and is effective against different Leishmania species (Nogueira et al. 2013) . Therefore, in the present work the anti-T. cruzi activity in vitro and in vivo of EEPA was evaluated.
Material and methods

Plant material
P. angulata specimens were collected and identified during the drier season (from June until November) in Belém, Pará State, Brazil. A voucher specimen was deposited in the Herbarium of the Department of Physiology from the University Federal of Pará (Voucher number 15).
Extraction and phytochemical analysis of P. angulata
Stems of P. angulata (1 kg) were dried and crushed. Then, extraction was carried out with ethanol at 50-60°C during 6 h. The extract was concentrated under reduced pressure, yielding 100 g (10%) of crude ethanolic extract. It was maintained in a desiccator under vacuum until weight stabilized. HPLC-UV analysis was determined in an Agilent HP 1100 series system consisting of an auto-sampler, high-pressure mixing pump and UV detector (Agilent Technologies, Santa Clara, CA). Samples were run in a reverse phase C-18 column 5 μm (250 mm × 4 mm, Hibar ® LiChrosorb ® , Merk, Germany) and UV absorbance was measured at 225 nm by injecting 10 μl of EEPA dissolved in 10 mg/ml in MeOH at flow rate 1 ml/min. Physalins in the EEPA were confirmed by comparing with standard isolated physalin previously characterized. These procedures were performed as described by Nogueira et al. (2013) and executed in accordance with European Medicines Agency guidelines for herbal products.
Drugs
Benznidazole (LAFEPE, Recife, Brazil) was used as reference drug in the anti-T. cruzi assays. Gentian violet (Synth, São Paulo, Brazil) was used as positive control in the cytotoxicity assays. All compounds were dissolved in DMSO (Sigma-Aldrich, St. Louis, MO) and diluted in cell culture medium for use in the assays. The final concentration of DMSO was less than 1% in all in vitro experiments.
Parasites
The T. cruzi strains Y (DTU II; Silva and Nussenzweig 1953) and Colombian (DTU I; Federici et al. 1964) were used in this study. T. cruzi epimastigotes were grown in liver infusion tryptose (LIT) medium supplemented with 10% fetal bovine serum (FBS; Cultilab, Campinas, Brazil), 1% hemin (Sigma-Aldrich), 1% R9 medium (Sigma-Aldrich) and 50 μg/ml of gentamycin (Novafarma, Anápolis, Brazil) at 26°C.
Tissue culture trypomastigotes were obtained from the supernatants of 5-to 6-day-old infected LLC-MK2 cells maintained in RPMI-1640 medium supplemented with 10% FBS and 50 μg/ml gentamycin at 37°C in a 5% humidified CO 2 atmosphere.
Animals
Female BALB/c mice (18-22 g) were provided by the animal breeding facility and maintained in sterilized cages under a controlled environment, water ad libitum and receiving a balanced diet for rodent at Centro de Pesquisa Gonçalo Moniz (Fundação Oswaldo Cruz, Bahia, Brazil) . All experiments were carried out in accordance with the recommendations of Ethical Issues Guidelines, and were approved by the local Animal Ethics Committee.
Assessment of cytotoxicity to macrophages
Peritoneal exudate macrophages were obtained by washing, with cold RPMI medium, the peritoneal cavity of BALB/c mice 4-5 days after injection of 3% thioglycolate in saline (1.5 ml per mice). Then, cells were seeded into 96-well plates at a cell number 1 × 10 5 cells/well in RPMI-1640 medium supplemented with 10% of FBS and 50 μg/ml of gentamycin and incubated for 24 h at 37°C and 5% CO 2 . After that time each sample was added at eight concentrations (0.02-50 μg/ml) in triplicate and incubated for 72 h. Twenty microliters/well of AlamarBlue (Invitrogen, Carlsbad, CA) were added to the plates during 10 h. Colorimetric readings were performed at 570 and 600 nm. CC 50 values were calculated using data-points gathered from three independent experiments. Gentian violet was used as positive control.
Antiparasitic activity
Epimastigotes (1 × 10 6 cells/well) were seeded in fresh medium in LIT medium in the absence or presence of the EEPA at eight concentrations (0.02-50 μg/ml) in triplicate. Cell growth was determined after culture for 5 days by counting viable forms in a Neubauer chamber. Bloodstream trypomastigotes forms of T. cruzi from the supernatants of previously infected LLC-MK2 cells were dispensed into 96-well plates (4 × 10 5 cell/well) in RPMI medium supplemented with 10% FBS and 50 μg/ml of gentamycin in the absence or presence of different concentrations (0.02-50 μg/ml) of the plant extract, in triplicate. Viable parasites were counted in a Neubauer chamber 24 h after incubation. The percentage of inhibition was calculated in relation to untreated cultures. To determine the inhibitory concentration of 50% (IC 50 ) and the effective concentration at 50% (EC 50 ) for epimastigote and trypomastigote forms of T. cruzi, respectively, a nonlinear regression on Prism 5.02 GraphPad software was employed. Experiments were performed in both Y and Colombian strains and benznidazole was used as anti-T. cruzi reference drug. For in vitro drug combinations, doubling dilutions of each drug (EEPA and benznidazole), used alone or in fixed combinations were incubated with 4 × 10 5 cells/well trypomastigotes (Y strain) for 24 h. The analysis of the combined effects was performed by determining the combination index (CI) by using Chou-Talalay CI method and the CompuSyn software version 1.0 (ComboSyn Inc., Paramus, NJ), as described previously (Chou and Talalay 2005) . CI values were used as cutoff to determine synergism.
T. cruzi-infected macrophages
Peritoneal exudate macrophages (2 × 10 5 cells/well) obtained from BALB/c mice were seeded in a 24 well-plate with rounded coverslips on the bottom in RPMI supplemented with 10% FBS and incubated for 24 h. Cells were then infected with trypomastigotes (10:1) for 2 h. Free trypomastigotes were removed by successive washes using saline solution and the cells were incubated for 24 h to allow full internalization and differentiation of trypomastigotes to amastigotes. Next, cultures were incubated in complete medium alone or with the EEPA or benznidazole (0.1-2.5 μg/ml) for 72 h. Cells were fixed in absolute alcohol and the percentage of infected macrophages and the number of amastigotes/100 macrophages was determined by manual counting after hematoxylin and eosin staining using an optical microscope (Olympus, Tokyo, Japan). The percentage of infected macrophages and the number of amastigotes per 100 macrophages was determined by counting 100 cells per slide. The one-way ANOVA and Bonferroni for multiple comparisons were used to determine the statistical significance of the group comparisons. Experiment was done with both strains (Y and Colombian) and benznidazole was used as positive control.
Propidium iodide and annexin V staining
T. cruzi trypomastigotes from Y strain (1 × 10 7 ) were incubated for 24 and 72 h at 37°C in the absence or presence of EEPA (1.7, 3.4 or 5 μg/ml). After incubation, the parasites were labeled for propidium iodide (PI) and annexin V using the annexin V-FITC apoptosis detection kit (Sigma-Aldrich), according to the manufacturer's instructions. Acquisition and analyses was performed using a FACS Calibur flow cytometer (Becton Dickinson, San Diego, CA), with FlowJo software (Tree Star, Ashland, OR). A total of 30.000 events were acquired in the region previously established as that corresponding to trypomastigotes forms of T. cruzi.
Infection in mice
Female BALB/c mice (18-22 g) were infected with bloodstream trypomastigotes by intraperitoneal inoculation of 10 4 parasites in 100 μl of saline solution and then mice were randomly divided in groups (six animals per group). After the day 5 of infection, treatment with 50 or 100 mg/kg weight of EEPA was given orally for 5 consecutive days. For the control group, benznidazole was given orally at dose of 100 mg/kg weight. Saline containing 20% DMSO was used as a vehicle and administrated on untreated and infected group. Animal infection was monitored daily by counting the number of motile parasites in 5 μl of fresh blood sample drawn from the lateral tail veins, as recommended by standard protocol (Brener 1962) . Survival was monitored for 30 days after treatment. The one-way ANOVA and Bonferroni for multiple comparisons were used to determine the statistical significance of the group comparisons.
Results
Extraction and phytochemical analysis of EEPA revealed that this extract is rich in seco-steroids, mainly physalins B, D, F and G. By HPLC-UV, it was estimated that each 100 mg of EEPA contains 0.84% of physalin B, 0.90% of physalin D, 0.37% of physalin F and 0.36% of physalin G. This is in agreement with the literature showing that this plant contains a number of steroids (Nogueira et al. 2013; Tomassini et al. 2000) .
The trypanocidal activity of EEPA was initially evaluated against epimastigotes and trypomastigotes (Y and Colombian strains) through the determination of IC 50 and EC 50 , respectively. The plant extract showed a potent anti-T. cruzi activity, being able to inhibit epimastigote proliferation and lyse trypomastigotes. The IC 50 of EEPA The activity of EPPA against intracellular amastigotes (Y strain) was also investigated. The plant extract induced a concentrationdependent reduction in the analyzed parameters: percentage of infected macrophages (Fig. 1A) and the mean number of intracellular amastigotes per infected macrophage (Fig. 1B) . Under the same conditions, a similar reduction was observed on treated-benznidazole macrophages. No signs of cytotoxicity were observed on macrophage cultures (data not shown).
After confirming that EEPA was able to decrease parasite viability, the mechanism of EEPA-induced cell death was investigated. In untreated cultures, most cells were negative for annexin V and PI staining, demonstrating cell viability ( Fig. 2A) . Cultures treated with EEPA showed a concentration and time-dependent increase in the number of PI-positive parasites when compared with untreated parasites (Fig. 2B-D) . Treatment with 3.4 μg/ml of EEPA for 72 h resulted in 11.5 and 41.3% of cells positive for PI and PI + annexin V, respectively, whereas 1.1% cells were stained only for annexin V. These results indicate that EEPA treatment increases the number of PI staining, which is characteristic of a parasite cell death caused by a necrotic process.
Next, in vivo studies to evaluate the effects of EEPA against T. cruzi infection in mice (acute phase) were performed. As shown in Fig. 3 , EEPA treatment significantly (P < 0.001) reduced blood parasitaemia when compared with mice treated with vehicle (Fig. 3) . At doses of 50 and 100 mg/kg, EEPA administration caused a reduction in blood parasitaemia of 42.6 and 72.7%, respectively (Table 2 ). In the group treated with benznidazole, it was observed >99% of inhibition of blood parasitaemia, indicating that eradication of infection was achieved. Treatment with EPPA, similar to the treatment with benznidazole, had a protective effect on mortality. Mice from benznidazole or EEPA treated groups did not show any behavioral alteration or signs of toxicity (data not shown).
Finally, the antiparasitic effect of EEPA and benznidazole in combination was investigated against trypomastigotes. In comparison to drug alone, the combination of EEPA and benznidazole reduced both EC 50 and EC 90 values. In fact, the EC 50 and EC 90 of benznidazole decreased in average by 59% when combined with EEPA (Table 3) , The combination index values revealed that EEPA and benznidazole have synergistic effects. Mouse peritoneal exudate macrophages were infected with Y strain trypomastigotes for 2 h and treated with different concentrations of EEPA (2.5, 1, 0.5 or 0.25 μg/ml) or benznidazole (2.5 μg/ml), a standard drug. Cells were stained with hematoxylin and eosin and analyzed by optical microscopy. The percentage of infected macrophages (A) and the relative number of amastigotes per 100 macrophages (B) were determined by counting hematoxylin and eosin-stained cultures. BDZ is benznidazole. Values represent the mean ± SEM of triplicates.
* P < 0.05; * * P < 0.01; * * * P < 0.001 compared to the control group. 
Discussion
In this study, the potent anti-T. cruzi activity of concentrated ethanolic extract from P. angulata (EEPA) rich in physalins was demonstrated in vitro on different strains of T. cruzi and in vivo on an acute model of infection. EEPA was chosen mainly because the isolation of the active molecule is costly, time consuming and gives a small fraction of material. On the other hand, the extract is easily obtained, has low cytotoxicity and high stability (Nogueira et al. 2013) .
EEPA effectively inhibits the growth of epimastigotes and was toxic against bloodstream trypomastigotes of T. cruzi. More importantly, has potent activity against amastigotes inside infected 4 Y strain trypomastigotes. Five days after infection, mice were treated orally with EEPA (50 or 100 mg/kg) or benznidazole (100 mg/kg) once a day during 5 consecutive days. Parasitemia was monitored by counting the number of trypomastigotes in fresh blood samples. Values represent the mean ± SEM of 6 mice per group. Results are from one experiment of two replicates performed.
* P < 0.05; * * * P < 0.001 compared to untreated-infected group (vehicle). macrophages (the clinically relevant form), without affecting mammalian cells. These observations confirm and extend the antiparasitic activity of EEPA recently reported by Nogueira et al. (2013) . The authors demonstrated that even in a low dose of EEPA is enough to reduce the percentage of infected cells, as well as the parasite burden in L. amazonensis-infected macrophages. Moreover, a high selectivity index was observed, pointing out the great efficacy against L. amazonensis (Nogueira et al. 2013) .
To identify the mechanism of cell death induced by EEPA treatment, analyses of the classical necrosis/apoptosis processes were performed. From the literature, it is well known that activation of cell death pathway depends on type, time, and intensity of the stimulus (Kessler et al. 2013) . Necrosis is usually defined as a process of cell collapse that involves oncosis (increase in cell volume), rupture of plasma membrane and the unorganized dismantling of swollen organelles. Apart from the presence of plasma membrane permeabilization, necrosis lacks specific biochemical markers (Kroemer et al. 2009 ). In this study, EEPA treatment caused an increase time-dependent in the number of PI-positive parasites, suggestive of cell death by necrosis. PI-positive parasites also were observed after 24 h of treatment with physalin B (Meira et al. 2013 ). In addition, ultrastructural analyses showed remarkable alterations in the morphology of the Golgi complex, kinetoplast, endoplasmic reticulum and plasma membrane of trypomastigotes, confirming a pattern consistent with necrotic cell death.
Combination therapies can be a valuable tool to improve treatment efficacy and reduce dose levels and toxicity, as well as to prevent the potential development of resistance, which may be advantages for the treatment of parasitic diseases (Vivas et al. 2008; Diniz et al. 2013) . In this study, EEPA demonstrates synergistic effects with benznidazole against the bloodstream parasites in vitro, showing a promising profile for drug combination.
In spite of the great potential of natural products for infectious disease treatment, the literature is relatively scarce of anti-T. cruzi natural products (Altei et al. 2014; Da Rocha et al. 2014; Sanchez et al. 2013; Santos et al. 2012; Valli et al. 2013) . Therefore the investigation of both crude and fractionated plant extracts is important. The findings reported here not only demonstrate that EEPA is a rich source of antiparasitic natural products, but also points out the necessity of more efforts toward exploring biodiversity for identifying anti-T. cruzi compounds.
Conclusion
EEPA demonstrated a strong, selective, and broad-spectrum antiparasitic activity against T. cruzi. Consistent with this strong in vitro activity, EEPA reduced parasite burden by rapidly interrupting the cell cycle in the obligated host. Mechanistically, this natural product achieved antiparasitic activity through induction cell death via necrosis. EEPA was able to reduce the course of an aggressive acute infection murine model and provided to a suitable partner for drug combination. The results presented herein reinforce the investigation of other members of this family for antiparasitic compounds.
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